Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar, Bruno Paiva, Kenneth C. Anderson, et al.
The Lancet Oncology (2016) Vol. 17, Iss. 8, pp. e328-e346
Closed Access | Times Cited: 2390

Showing 1-25 of 2390 citing articles:

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi, Larry D. Anderson, Nina Shah, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 8, pp. 705-716
Open Access | Times Cited: 1728
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios Α. Dimopoulos, Albert Oriol, Hareth Nahi, et al.
New England Journal of Medicine (2016) Vol. 375, Iss. 14, pp. 1319-1331
Open Access | Times Cited: 1336
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani, et al.
The Lancet (2021) Vol. 398, Iss. 10297, pp. 314-324
Closed Access | Times Cited: 1175
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal, Valérie Lauwers‐Cancès, Cyrille Hulin, et al.
New England Journal of Medicine (2017) Vol. 376, Iss. 14, pp. 1311-1320
Open Access | Times Cited: 1079
Multiple myeloma
Shaji Kumar, S. Vincent Rajkumar, Robert A. Kyle, et al.
Nature Reviews Disease Primers (2017) Vol. 3, Iss. 1
Closed Access | Times Cited: 957
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo, et al.
New England Journal of Medicine (2017) Vol. 378, Iss. 6, pp. 518-528
Open Access | Times Cited: 872
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Thierry Façon, Shaji Kumar, Torben Plesner, et al.
New England Journal of Medicine (2019) Vol. 380, Iss. 22, pp. 2104-2115
Open Access | Times Cited: 840
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau, Michel Attal, Cyrille Hulin, et al.
The Lancet (2019) Vol. 394, Iss. 10192, pp. 29-38
Open Access | Times Cited: 828
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Philippe Moreau, Jesús F. San Miguel, Pieter Sonneveld, et al.
Annals of Oncology (2017) Vol. 28, pp. iv52-iv61
Open Access | Times Cited: 807
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial, Hans C. Lee, Ashraf Badros, et al.
The Lancet Oncology (2019) Vol. 21, Iss. 2, pp. 207-221
Closed Access | Times Cited: 685
Teclistamab in Relapsed or Refractory Multiple Myeloma
Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 6, pp. 495-505
Open Access | Times Cited: 656
B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
Adam D. Cohen, Alfred L. Garfall, Edward A. Stadtmauer, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 6, pp. 2210-2221
Open Access | Times Cited: 654
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
S. Vincent Rajkumar
American Journal of Hematology (2020) Vol. 95, Iss. 5, pp. 548-567
Open Access | Times Cited: 636
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Meletios Α. Dimopoulos, Philippe Moreau, Evangelos Terpos, et al.
Annals of Oncology (2021) Vol. 32, Iss. 3, pp. 309-322
Open Access | Times Cited: 600
Multiple myeloma
Niels W.C.J. van de Donk, Charlotte Pawlyn, Kwee Yong
The Lancet (2021) Vol. 397, Iss. 10272, pp. 410-427
Closed Access | Times Cited: 588
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter M. Voorhees, Jonathan L. Kaufman, Jacob P. Laubach, et al.
Blood (2020) Vol. 136, Iss. 8, pp. 936-945
Open Access | Times Cited: 573
Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou, et al.
New England Journal of Medicine (2019) Vol. 381, Iss. 8, pp. 727-738
Open Access | Times Cited: 562
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
S. Vincent Rajkumar
American Journal of Hematology (2022) Vol. 97, Iss. 8, pp. 1086-1107
Open Access | Times Cited: 555
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
Juan Flores‐Montero, Luzalba Sanoja-Flores, Bruno Paiva, et al.
Leukemia (2017) Vol. 31, Iss. 10, pp. 2094-2103
Open Access | Times Cited: 542
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
Michèle Cavo, Evangelos Terpos, Cristina Nanni, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 4, pp. e206-e217
Closed Access | Times Cited: 451
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
Zuan-Fu Lim, C. Patrick
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 442
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
Nelson Leung, Frank Bridoux, Vecihi Batuman, et al.
Nature Reviews Nephrology (2018) Vol. 15, Iss. 1, pp. 45-59
Open Access | Times Cited: 441
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Thomas G. Martin, Saad Z. Usmani, Jesús G. Berdeja, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 6, pp. 1265-1274
Open Access | Times Cited: 398
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
Jens Hillengaß, Saad Z. Usmani, S. Vincent Rajkumar, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 6, pp. e302-e312
Open Access | Times Cited: 394
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
María‐Victoria Mateos, Michèle Cavo, Joan Bladé, et al.
The Lancet (2019) Vol. 395, Iss. 10218, pp. 132-141
Closed Access | Times Cited: 394
Page 1 - Next Page

Scroll to top